AstraZeneca presented new data underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...
These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
The FDA has issued a Complete Response Letter regarding the New Drug Application for investigational compound dapagliflozin from BMS/AstraZeneca for...
AstraZeneca and Bristol-Myers Squibb Company announced that the FDA has acknowledged receipt of the New Drug Application (NDA) resubmission for...
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and alone, compared with placebo in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73m2.
AstraZeneca announced positive results from a Phase III study comparing the efficacy and safety of dapagliflozin versus placebo as an...
The peer-reviewed article describes clinical evidence for the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in the treatment of chronic kidney disease.
In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes
The National Institute for Health and Care Excellence (NICE) has, in draft guidance, recommended Forxiga (dapagliflozin) from AstraZeneca, Invokana (canagliflozin)...
The National Institute for Health and Care Excellence (NICE) has recommended Forxiga (dapagliflozin) from AstraZeneca as part of a triple...